Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech.
123I-FP-CIT (DAT scan) SPECT
Corticobasal syndrome (CBS)
Dopamine receptor
Parkinsonism
Progressive apraxia of speech (PAOS)
Progressive supranuclear palsy (PSP)
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
06
01
2020
accepted:
02
05
2020
revised:
29
04
2020
pubmed:
11
5
2020
medline:
22
6
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
To describe PAOS is a neurodegenerative syndrome in which patients present with apraxia of speech, a motor speech disorder affecting programming and planning of speech. Patients with PAOS predictably develop Parkinsonism. DAT scan is a neuroimaging tool that assesses the integrity of presynaptic dopamine transporters in striatum and is usually abnormal in PSP and CBS. As part of an NIH-funded grant, we performed a DAT scan on 17 PAOS patients early in the disease course. DaTQUANT software was used to quantify uptake in the left and right caudate and anterior/posterior putamen, with striatum to background ratios (SBRs). The PAOS cohort was compared to 15 PSP and 8 CBS patients. Five PAOS patients (29%) showed abnormalities in at least one striatal region on DAT scan. When the five PAOS patients with abnormal DAT were compared to the PSP and CBS patients, the only difference observed was lower uptake in the posterior putamen in PSP (p = 0.03). There were no differences is putamen/caudate ratio or in symmetry of uptake, across all groups. There was also no difference in MDS-UPDRS-III scores between PAOS patients with and without abnormal DAT scans (p = 0.56). Abnormal DAT scan is observed early in the disease course in approximately 30% of PAOS patients, with striatal abnormalities similar to those in PSP and CBS.
Sections du résumé
OBJECTIVE
OBJECTIVE
To describe
BACKGROUND
BACKGROUND
PAOS is a neurodegenerative syndrome in which patients present with apraxia of speech, a motor speech disorder affecting programming and planning of speech. Patients with PAOS predictably develop Parkinsonism. DAT scan is a neuroimaging tool that assesses the integrity of presynaptic dopamine transporters in striatum and is usually abnormal in PSP and CBS.
METHODS
METHODS
As part of an NIH-funded grant, we performed a DAT scan on 17 PAOS patients early in the disease course. DaTQUANT software was used to quantify uptake in the left and right caudate and anterior/posterior putamen, with striatum to background ratios (SBRs). The PAOS cohort was compared to 15 PSP and 8 CBS patients.
RESULTS
RESULTS
Five PAOS patients (29%) showed abnormalities in at least one striatal region on DAT scan. When the five PAOS patients with abnormal DAT were compared to the PSP and CBS patients, the only difference observed was lower uptake in the posterior putamen in PSP (p = 0.03). There were no differences is putamen/caudate ratio or in symmetry of uptake, across all groups. There was also no difference in MDS-UPDRS-III scores between PAOS patients with and without abnormal DAT scans (p = 0.56).
CONCLUSIONS
CONCLUSIONS
Abnormal DAT scan is observed early in the disease course in approximately 30% of PAOS patients, with striatal abnormalities similar to those in PSP and CBS.
Identifiants
pubmed: 32388831
doi: 10.1007/s00415-020-09883-4
pii: 10.1007/s00415-020-09883-4
pmc: PMC7426240
mid: NIHMS1604523
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Iodine Radioisotopes
0
Nortropanes
0
Receptors, Dopamine
0
Tropanes
0
Iodine-123
8YWR746RPQ
ioflupane
VF232WE742
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2603-2611Subventions
Organisme : NIDCD NIH HHS
ID : R01 DC012519
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC014942
Pays : United States
Organisme : NIH HHS
ID : R01DC12519
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01DC14942
Pays : United States
Références
J Neurol Sci. 2018 Feb 15;385:17-21
pubmed: 29406901
Can J Neurol Sci. 1997 Feb;24(1):29-36
pubmed: 9043744
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Am J Neurodegener Dis. 2013;2(1):29-34
pubmed: 23515233
Neurology. 2013 Jul 23;81(4):337-45
pubmed: 23803320
Mov Disord. 2006 Oct;21(10):1724-7
pubmed: 16773621
Neurol Sci. 2003 Oct;24(3):149-50
pubmed: 14598060
Mov Disord. 2009 Mar 15;24(4):500-8
pubmed: 19117369
Ann Neurol. 2003;54 Suppl 5:S15-9
pubmed: 12833363
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Neurology. 2005 Dec 27;65(12):1863-72
pubmed: 16237129
Mov Disord. 2000 Nov;15(6):1158-67
pubmed: 11104200
Brain. 2012 May;135(Pt 5):1522-36
pubmed: 22382356
J Parkinsons Dis. 2019;9(3):553-563
pubmed: 31306141
Med Law. 1998;17(1):7-11
pubmed: 9646588
Ann Neurol. 2017 Sep;82(3):419-428
pubmed: 28833467
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Mov Disord Clin Pract. 2019 May 29;6(6):452-461
pubmed: 31392246
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Arch Neurol. 2011 Jun;68(6):753-60
pubmed: 21670399
Am J Speech Lang Pathol. 2018 Nov 21;27(4):1303-1318
pubmed: 30458509
Neuroimage Clin. 2016 Jul 05;12:234-40
pubmed: 27489771
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Neurology. 1998 Dec;51(6):1546-54
pubmed: 9855500
Neurology. 2014 May 20;82(20):1791-7
pubmed: 24759846
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
J Neurol Sci. 2006 May 15;244(1-2):103-9
pubmed: 16473371
Aphasiology. 2014 Aug;28(8-9):1004-1017
pubmed: 25309017
Brain. 2006 Jun;129(Pt 6):1385-98
pubmed: 16613895
Neurocase. 2005 Aug;11(4):283-96
pubmed: 16093229
Brain. 2014 Oct;137(Pt 10):2783-95
pubmed: 25113789
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Brain Lang. 2018 Sep;184:54-65
pubmed: 29980072
J Nucl Med. 2020 Mar 20;:
pubmed: 32198310
Neurocase. 2018 Apr;24(2):111-120
pubmed: 29799310